Julie Kerr-Conte (BSc, MSc, PhD) is Professor of Cell Biology/Cell Therapy at the University of Lille, France, where she works in the INSERM U1190 team on Translational Research for Diabetes. She completed a BSc from SUNY Albany, New York in 1986, her MSc from the University of Wisconsin, Madison in 1990 and her PhD from the Science and Technology University, Lille 1 in 1995.

She is responsible for research and clinical grade human islet isolation (French FDA [ANSM]-approved process) and Director of the core Biotherapies Platform since 2012 (French FDA-approved facility) Deputy Director, INSERM U1190 Translational Research for Diabetes. She is a recognised technical expert and a faculty member of NICE Networks of Islet Cell Transplantation in Europe. She is responsible for the manned Biotherapies Platform, authorised by the French FDA for auto- and allograft cell therapy of diabetes (171 islet allo/autotransplants in 70 patients).  She has published more than 200 articles in peer-reviewed journals.

Profess Kerr-Conte is a member of the EASD, the International Pancreas and Islet Transplantation Association and a Board member of Artificial Insulin Delivery Pancreas and islet Transplant and the European Islet and Pancreas Transplantation Association, a member of the European Society for Organ Transplantation and an elected member of CNU (Conseil National des Universit├ęs) in Cell Biology (65).